Cyproterone acetate/ethinylestradiol | Drospirenone/ethinylestradiol | Levonorgestrel/ethinylestradiol | ||||
---|---|---|---|---|---|---|
Diagnosis/indication | 2002 (n=1595) | 2010 (n=1599) | 2002 (n=1009) | 2010 (n=3373) | 2002 (n=5632) | 2010 (n=9633) |
Acne | 813 (51.0) | 1266 (79.2) | 119 (11.8) | 831 (24.6) | 471 (8.4) | 868 (9.0) |
Hirsutism | 48 (3.0) | 80 (5.0) | 2 (0.2) | 16 (0.5) | 2 (0.04) | 9 (0.1) |
Polycystic ovary syndrome | 70 (4.4) | 46 (2.9) | 7 (0.7) | 38 (1.1) | 8 (0.1) | 26 (0.3) |
Oligomenorrhoea | 16 (1.0) | 11 (0.7) | 15 (1.5) | 26 (0.8) | 50 (0.9) | 62 (0.6) |
Infertility/anovulation | 1 (0.1) | 0 (0) | 0 (0) | 2 (0.1) | 2 (0.04) | 8 (0.1) |
Alopecia | 15 (0.9) | 4 (0.3) | 4 (0.4) | 13 (0.4) | 18 (0.3) | 34 (0.4) |
Gynaecological disorders* | 107 (6.7) | 55 (3.4) | 160 (15.9) | 531 (15.7) | 815 (14.5) | 1958 (20.3) |
Contraception | 525 (32.9) | 137 (8.6) | 702 (69.6) | 1916 (56.8) | 4266 (75.7) | 6668 (69.2) |
Read code for contraception | 472 (89.9) | 130 (94.9) | 643 (91.6) | 1752 (91.4) | 3711 (87.0) | 6107 (91.6) |
No Read code† | 53 (10.1) | 7 (5.1) | 59 (8.4) | 164 (8.6) | 555 (13.0) | 561 (8.4) |
*Gynaecological disorders include dysmenorrhoea, menorrhagia, irregular menstruation, premenstrual syndrome, uterine fibroids, endometriosis and dyspareunia.
†In the absence of a Read code indicating use for contraception or to treat hormone-responsive conditions, women were assumed to have been using the product for contraception.